Cost of Nivolumab in Combination with Ipilimumab As First Line Treatment in Advanced Melanoma Across Various European Markets
Abstract
Authors
O Ovcinnikova F Bourhis M Shah R Potluri O Chirita J Sabater P Di Rienzo
O Ovcinnikova F Bourhis M Shah R Potluri O Chirita J Sabater P Di Rienzo
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now